Yakult option puts LivTech on track for cancer antibody deal
This article was originally published in Scrip
Executive Summary
Following a setback earlier this year, the privately held Japanese bioventure LivTech has bounced back with a new deal for one of its main streams of research, signing an option agreement with Yakult Honsha for a series of novel anticancer antibodies.